Stereotactic Ablative Radiotherapy (SAbR) for Treatment of Ventricular Tachycardia (VT) Refractory Standard Invasive Ablation Techniques
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Tachycardia, Ventricular
- Sponsor
- University of Texas Southwestern Medical Center
- Locations
- 1
- Primary Endpoint
- Primary efficacy outcome of ICD (implantable cardioverter-defibrillator) Treatment
- Status
- Withdrawn
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the clinical efficacy and safety of stereotactic ablative radiotherapy (SAbR), also known as stereotactic body radiation therapy (SBRT), for treatment of ventricular tachycardia (VT) requiring implantable cardioverter defibrillator (ICD) treatments in patients with VT refractory to standard invasive ablation techniques. We hypothesized that SAbR is effective in suppressing sustained VT and reducing ICD treatments in this group of patients and is associated with acceptably low risk of serious complications.
Investigators
James Daniels
ASSOC PROFESSOR
University of Texas Southwestern Medical Center
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years
- •Have an ICD implanted \> 6 months and all VT episodes in the past 6 months are available in device memory.
- •Within the past 3 months, the patient has at least one episode of symptomatic monomorphic VT that requires ICD treatment (anti-tachycardia pacing and/or ICD shock) or was sustained/incessant but falls under ICD treatment zone. These VT episodes must occur after at least one standard invasive VT ablation or occur in a patient that is clinically deemed not eligible to the standard VT ablation procedure.
- •Two independent cardiac electrophysiologists reviewed the case and agreed that the patient would benefit from suppression of these VT episodes but there is no optimal invasive VT ablation or antiarrhythmic drug options.
Exclusion Criteria
- •Has contraindication to receive SAbR or VT clinically deemed not suitable for SAbR.
- •Is pregnant
- •Has severe co-morbid medical condition or terminal illness and is unlikely to survive more than 6 months regardless of VT status based on clinical judgement by treating or enrolling physicians.
- •On potent immunosuppressive therapy (e.g., post organ transplant)
- •Has severe collagen vascular disorder with organ involvement
- •Not willing or not able to consent to participate in the study
Outcomes
Primary Outcomes
Primary efficacy outcome of ICD (implantable cardioverter-defibrillator) Treatment
Time Frame: 6 months
Number of episodes of ICD (implantable cardioverter-defibrillator) treatment (including both ATP and shock) per month; comparing 6 months before and after SAbR (excluding the first 2-week blanking period post SAbR).